The European venture firm Medicxi has successfully raised 500 million euros, approximately $579 million, for its fifth fund aimed at supporting ‘asset-centric’ startups in the biotech sector. This significant capital influx comes on the heels of a series of recent buyout transactions involving its portfolio companies, such as Merus and Vicebio, indicating a robust interest in innovative biotech solutions.
This latest funding round underscores a growing trend among venture capitalists to focus on companies with tangible assets and clear developmental pathways. As the biotech landscape becomes increasingly competitive, the ability to attract substantial investment will be crucial for startups seeking to navigate regulatory hurdles and bring their products to market. Medicxi’s strategic emphasis on asset-centric models may not only enhance the success rates of its investments but also signal a shift in investor priorities within the pharmaceutical industry.
Use the database as your supply chain compass →
